RBBP6 and cancer: from molecular mechanisms to clinical implications
Résumé
Retinoblastoma binding protein 6 (RBBP6) is a 200 kDa E3 ubiquitin ligase that performs several biological functions and plays a role in tumorigenesis. RBBP6 is overexpressed in several types of tumors, including lung, colorectal, breast, cervical, hepatocellular, and esophageal cancers, suggesting its association with malignant progression. Moreover, this increased expression has been associated with clinicopathological parameters in lung, colorectal, cervical, and ovarian cancers. This review captures the molecular functions of RBBP6 and the mechanisms by which aberrant RBBP6 expression and function influence cancer development and therapeutic response. These mechanisms include its ability to interact with E3 ligase substrates, Jun N-terminal kinase (JNK), noncoding RNAs, and DNA damage-associated proteins to promote cell proliferation, stemness, cell cycle progression, and metastasis. We also evaluated the prognostic and predictive significance of RBBP6 as a potential cancer biomarker and its suitability as a molecular target in cancer. This is the first review that comprehensively explores the multifaceted molecular mechanisms by which RBBP6 influences cancer progression in several cancer types.
Citer ce document
Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)
Accès au document
Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter
Voir l'article sur le site de la revueLicence et provenance
Licence : CC BY
Notice moissonnée depuis OpenAlex le 30/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →